HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Online-Only Appendix All Versions of this Article: db07-0859v1 57/2/503    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bellanné-Chantelot, C. Articles by Timsit, J. Search for Related Content PubMed PubMed Citation Articles by Bellanné-Chantelot, C. Articles by Timsit, J. Social Bookmarking                What's this?

The Type and the Position of HNF1A Mutation Modulate Age at Diagnosis of Diabetes in Patients with Maturity-Onset Diabetes of the Young (MODY)-3

¹ Department of Genetics, AP-HP Groupe Hospitalier Pitié-Salpétrière, Université Pierre et Marie Curie-Paris6, Paris, France
² Department of Immunology and Diabetology, AP-HP Hôpital Cochin, Université René Descartes- Paris5, and Inserm, Research Unit 561, Paris, France
³ Department of Endocrinology, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France
⁴ Department of Nutrition-Metabolic Diseases-Endocrinology, AP-HM CHU de la Timone, Marseille, France
⁵ Department of Endocrinology, AP-HP Hôpital Saint-Louis, Université Denis Diderot-Paris7, Paris, France
⁶ Department of Diabetology, AP-HP Hôpital Bichat, Paris, France
⁷ Department of Endocrinology, CHU Caen, Caen, France
⁸ Department of Endocrinology, CHU Angers, Angers, France
⁹ Department of Diabetology, AP-HP Hôpital Hôtel Dieu, Paris, France
¹⁰ Department of Diabetology, AP-HP Groupe Hospitalier Pitié-Salpétrière, Université Pierre et Marie Curie-Paris6, Paris, France
¹¹ Department of Endocrinology, CHU Bretonneau, Tours, France
¹² Department of Endocrinology, CHU Nantes, Nantes, France
¹³ Department of Internal Medicine, AP-HP Hôpital Lariboisière, Paris, France
¹⁴ Department of Internal Medicine, Centre Hospitalier Saint-Morand, Altkirch, France
¹⁵ Department of Diabetology, Hôpital Beauregard, Thionville, France
¹⁶ Department of Endocrinology, AP-HP Hôpital Saint-Antoine, Paris, France
¹⁷ Department of Diabetology, CHU Nancy, Nancy, France
¹⁸ Department of Diabetology, CHU Strasbourg, Strasbourg, France
¹⁹ Department of Endocrinology, AP-HP Hôpital Cochin, Université Paris 5, Paris, France
²⁰ Department of Internal Medicine, Centre Hospitalier Compiègne, Compiègne, France
²¹ Inserm, Research Unit 695, Paris, France

Address correspondence and reprint requests to Christine Bellanné-Chantelot, Département de Génétique, Groupe Hospitalier Pitié-Salpétrière, Bât 6 rue Lapeyronie, 47/83 Boulevard de l’Hôpital, 75651 Paris Cedex 13, France. E-mail: christine.bellanne-chantelot{at}psl.aphp.fr

Key Words: HNF1A, hepatocyte nuclear factor 1- • MODY, maturity-onset diabetes of the young

	ABSTRACT

TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES

 
OBJECTIVE—The clinical expression of maturity-onset diabetes of the young (MODY)-3 is highly variable. This may be due to environmental and/or genetic factors, including molecular characteristics of the hepatocyte nuclear factor 1- (HNF1A) gene mutation.

RESEARCH DESIGN AND METHODS—We analyzed the mutations identified in 356 unrelated MODY3 patients, including 118 novel mutations, and searched for correlations between the genotype and age at diagnosis of diabetes.

RESULTS—Missense mutations prevailed in the dimerization and DNA-binding domains (74%), while truncating mutations were predominant in the transactivation domain (62%). The majority (83%) of the mutations were located in exons 1- 6, thus affecting the three HNF1A isoforms. Age at diagnosis of diabetes was lower in patients with truncating mutations than in those with missense mutations (18 vs. 22 years, P = 0.005). Missense mutations affecting the dimerization/DNA-binding domains were associated with a lower age at diagnosis than those affecting the transactivation domain (20 vs. 30 years, P = 10^–4). Patients with missense mutations affecting the three isoforms were younger at diagnosis than those with missense mutations involving one or two isoforms (P = 0.03).

CONCLUSIONS—These data show that part of the variability of the clinical expression in MODY3 patients may be explained by the type and the location of HNF1A mutations. These findings should be considered in studies for the search of additional modifier genetic factors.

Heterozygous mutations in the hepatocyte nuclear factor 1- (HNF1A) gene cause maturity-onset diabetes of the young (MODY)-3 (1,2). MODY3 is characterized by a severe insulin secretion defect, a retained sensitivity to sulfonylureas, a decreased renal threshold for glucose reabsorption, and, in rare families, the occurrence of liver adenomatosis (3–6).

The clinical expression of MODY3 is highly variable from one family to another or even within the same family (7). HNF1A mutation carriers may be normoglycemic while their siblings may be hyperglycemic at a comparable age (8). Symptoms at diagnosis may be variable. Some patients have metabolic decompensation, while in others diabetes is diagnosed by systematic screening. The severity and the course of insulin secretion defect also vary since approximately one-third of the patients are treated with insulin after 15 years of diabetes duration, whereas others control their diabetes by diet or oral hypoglycemic agents (9).

As in other monogenic diseases, this phenotype variability may be explained by environmental and/or additional genetic factors. Two studies have shown that age at diagnosis of diabetes in offspring carrying a HNF1A mutation was lower by 5–10 years when maternal diabetes was diagnosed before pregnancy, suggesting the role of exposure of the fetus to maternal hyperglycemia (10,11). Modifier genetic factors may also modulate the phenotype of the disease. Age at onset of diabetes is partly inheritable within MODY3 families, and putative genetic modifier loci have been mapped but not identified yet (12). In the same vein, it has been recently shown that germ line CYP1B1 heterozygous mutations, which affect estrogen metabolism, may increase the incidence of hepatocellular adenomas in women with MODY3 (13). The molecular characteristics of the HNF1A mutation may also play a role in the severity of the disease. About 200 different mutations have been reported in HNF1A (14). HNF1A is composed of three functional domains, and three isoforms are generated by alternative splicing, with different transcriptional properties and tissue expression patterns (15,16). A recent analysis of the HNF1A mutation spectrum showed no correlation between the age of onset of diabetes and the type of the mutation (16). An older age of onset was observed in MODY3 patients carrying a HNF1A missense mutation affecting specifically the HNF1A(A) isoform, which is highly expressed in the fetal pancreas (16).

Here, we describe the spectrum of HNF1A mutations identified in 356 unrelated MODY3 patients, and we show relationships between age at diagnosis of diabetes and the type and position of the mutations.

	RESEARCH DESIGN AND METHODS

TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES

 
Patients.
This study includes 356 unrelated patients (87% Euro-Caucasians, 60% women) who had been referred for genetic testing from 1998 to 2007 and in whom a HNF1A mutation was identified. All patients gave written informed consent.

Mutation analysis.
Several criteria were used to ascertain that the novel mutations identified in the present study were pathogenic: nature of the amino acid change, conservation of the residue across species, absence of the mutation in 300 control subjects of Euro-Caucasian origin, and cosegregation of the mutation with young-onset diabetes, when relatives were available.

The molecular spectrum of HNF1A mutations was analyzed according to three criteria. First, mutations were classified into two groups according to their predicted functional consequences. One group included missense mutations resulting in amino acid changes, and the second included nonsense, small insertions/deletions, or splicing mutations, predicted to generate premature stop codons (referred to as "truncating mutations"). Second, mutations were analyzed according to the three HNF1A functional domains: NH₂-terminal dimerization domain (amino acids 1–32), DNA-binding domain (amino acids 91–281), and COOH-terminal transactivation domain (282–631) (Fig. 1A) (17). Third, mutations were analyzed according to the affected isoforms of HNF1A. The HNF1A(A) isoform is the full-length transcript comprising the 10 exons, whereas HNF1A(B) and HNF1A(C) isoforms result from alternative splicing and contain the first seven and first six exons, respectively (Fig. 1B). Three groups of mutations were considered: mutations located in exons 1–6, affecting the three isoforms; mutations located in exon 7, affecting isoforms HNF1A(A) and (B); mutations located in exons 8–10, involving only the HNF1A(A) isoform.

View larger version (18K): [in this window] [in a new window]   FIG. 1. HNF1A mutational spectrum according to the genomic and isoform structures. A: The three functional domains are identified on the genomic sequence in dark gray (dimerization domain), mid-gray (DNA binding domain), and light gray (transactivation domain). Each exon is represented by a numbered box. B: The exons transcribed in the three HNF1A isoforms are indicated and colored according to the number of affected isoforms: the mid-gray boxes correspond to exons common to the three isoforms; the dotted box corresponds to exon 7 specific to the HNF1A(A) and (B) isoforms; and the white boxes correspond to exons specific to HNF1A(A). The numbers of mutations are indicated under the corresponding affected domain or isoform.

	RESULTS

TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES

 
Characteristics of the HNF1A mutational spectrum.
Among the 356 unrelated patients, 169 HNF1A mutations were identified. Fifty-one have previously been reported, whereas 118 are novel. The 51 known mutations were detected in 200 patients (supplementary Table [available at http://dx.doi.org/10.2337/db07-0859]). By contrast, the 118 novel mutations were mainly private mutations (97 of 118, 82%) (Table 1).

The same numbers of mutations affected the dimerization and DNA-binding domains (the two structurally major domains) and the transactivation domain (179 and 177 cases, respectively). However, missense mutations were much more frequent than truncating ones in the dimerization and DNA-binding domains (74% were missense mutations), while the opposite was noted in the transactivation domain (62% were truncating mutations) (Fig. 1A). The distribution was the same when considering only distinct mutations (not shown).

A large majority (83%) of the mutations were located in exons 1–6, thus affecting the three HNF1A isoforms; 13% of the mutations, located in exons 8–10, specifically affected the HNF1A(A) isoform; and 4% were located in exon 7, affecting isoforms HNF1A(A) and (B). This distribution within the isoforms was very similar when considering either missense or truncating mutations and when considering all or distinct mutations (Fig. 1B).

Age at diagnosis of diabetes according to the type and the position of the HNF1A mutations.
Age at diagnosis of diabetes was available for 352 patients. Median age at diagnosis was lower by 4 years in patients with truncating mutations than in those with missense mutations (18 vs. 22 years respectively, P = 0.005).

There was no difference in the age at diagnosis according to the location of the mutation within the dimerization/DNA-binding or transactivation domains (19 and 21.5 years, respectively) (Table 2). However, when both the type of the mutation and its position within the functional domains were considered, marked differences appeared. First, truncating mutations were associated with a lower age at diagnosis than missense ones when they affected the transactivation domain (19 vs. 30 years, P < 10^–4). By contrast, age at diagnosis was similar for truncating and missense mutations of the dimerization/DNA binding domain (18 and 20 years, respectively). Second, missense mutations affecting the dimerization/DNA-binding domains were associated with a lower age at diagnosis than missense mutations affecting the transactivation domain (20 vs. 30 years, P = 10^–4).

Because the functional domains and the isoform structure are overlapping within the first six exons (Fig. 1), we compared age at diagnosis associated with missense mutations located in the dimerization/DNA-binding domains (amino acids 1–281) with that associated with missense mutations located in the part of the transactivation domain common to the three isoforms (amino acids 282–437). Age at diagnosis was lower in the former than in the latter (20 vs. 26.5 years, respectively, P = 0.015).

	DISCUSSION

TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES

 
This large series of HNF1A mutations in 356 unrelated MODY3 patients emphasizes the high allelic heterogeneity of HNF1A. Among the 169 distinct mutations, 118 were not reported in a recent update (14). The large majority (82%) of the novel mutations were private. The type of mutations differed markedly within functional domains: in the dimerization/DNA-binding domain, 74% of the mutations were missense, whereas in the transactivation domain, truncating mutations were predominant (62%). A similar distribution of HNF1A mutations has previously been reported (14). Some missense mutations may have mild functional consequences on the protein, and their clinical expression may depend on the functional importance of the affected domain. Thus, some missense mutations of the transactivation domain may not be associated with overt diabetes or lead to a milder phenotype suggesting type 2 diabetes. In patients with truncating mutations, the mean age at diagnosis of diabetes was 18. This is similar to that previously reported in a large series of MODY3 patients (16) and suggests that truncating mutations have similar functional consequences. Nonsense-mediated decay may be the common mechanism leading to this homogenous phenotype through haplo-insufficiency (18). In patients with missense mutations, diabetes was diagnosed later (by 4 years on average) than in those with truncating mutations. This is in contrast with previous results that did not show relationship between the type of the mutations and age at onset (16). However, we only studied probands, while in the study by Harries et al., 55% of the MODY3 patients were relatives (16). We suggest that analyzing relatives together with the probands may introduce a bias toward the inclusion of young subjects through family screening. This would decrease the median age at diagnosis. Moreover, our diagnosis criteria are less restrictive than those often used to raise the diagnosis of MODY3, since we included probands with an age of onset of diabetes above 25 years.

Further analysis combining the type of the mutation and its location within the functional domains revealed striking differences in the age at diagnosis of diabetes. Diabetes was revealed 10 years earlier in patients carrying missense mutations located in the dimerization/DNA-binding domains than in those with a missense mutation in the transactivation domain. We hypothesize that missense mutations affecting the dimerization/DNA-binding domain have more severe functional consequences, such as impaired DNA-binding and protein stability (19).

Recently, it has been shown that the age at onset of diabetes may be influenced by the position of the mutation relative to HNF1A isoforms. Missense mutations located in exons eight to 10, that are specific of the HNF1A(A) isoform, were associated with an older age of onset (16). The authors suggested that this was due to differences in the expression level of the various isoforms in fetal and adult pancreas. We found that patients harboring missense mutations located in exon 7 or in exons 8–10 were diagnosed more than 10 years later than those with mutations in exons 1–6. However, since exons 1–6 include the dimerization and DNA-binding domains, the observed effect on age at diagnosis could be due either to involvement of the three isoforms or to the position of the mutation within the dimerization/DNA-binding domains (Fig. 1). To distinguish between these two possibilities, we compared mutations affecting the dimerization/DNA-binding domain to that affecting the first part of the transactivation domain, and we observed a younger age at onset in the former than in the latter. Thus, the location of the mutation within a domain crucial for the function of the protein overcomes the fact that the mutation affects the three isoforms of HNF1A. This was confirmed by a multivariate analysis (not shown).

The wide variability of MODY3 phenotype has suggested the role of modifier genes. However, such genes have not been identified yet (12). We have shown that truncating mutations, as compared with missense mutations, have an effect on the clinical expression of the disease. Moreover, in patients with missense mutations, which represent more than half of the cases, the position of the mutation relative to the functional domains of HNF1A also plays a role in the severity of the disease. We suggest that these parameters should be considered in the studies aiming at the identification of other factors that may influence the clinical expression of MODY3.

	ACKNOWLEDGMENTS

 
We thank all participants of the French Study Group of MODY for referring the patients and communication of clinical data. We thank Sandrine Beaufils, Florence Bellanger, Séverine Clauin, Sandrine Gobrecht, Gwendoline Leroy, and Christelle Vaury of the Molecular Genetics Laboratory for MODY genetic screening.

	FOOTNOTES

 
Published ahead of print at http://diabetes.diabetesjournals.org on 14 November 2007. DOI: 10.2337/db07-0859.

Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/db07-0859.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received for publication June 26, 2007 and accepted in revised form November 7, 2007

	REFERENCES

TOP ABSTRACT RESEARCH DESIGN AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Frayling TM, Bulamn MP, Ellard S, Appleton M, Dronsfield MJ, Mackie AD, Baird JD, Kaisaki PJ, Yamagata K, Bell GI, Bain SC, Hattersley AT: Mutations in the hepatocyte nuclear factor-1alpha gene are a common cause of maturity-onset diabetes of the young in the U.K. Diabetes 46:720–725, 1997[Abstract]
2. Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, Vaxillaire M, Southam L, Cox RD, Lathrop GM, Boriraj VV, Chen X, Cox NJ, Oda Y, Yano H, Le Beau MM, Yamada S, Nishigori H, Takeda J, Fajans SS, Hattersley AT, Iwasaki N, Hansen T, Pedersen O, Polonsky KS, Bell GI, et al.: Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 384:455–458, 1996[Medline]
3. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT: Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 362:1275–1281, 2003[Medline]
4. Bluteau O, Jeannot E, Bioulac-Sage P, Marques JM, Blanc JF, Bui H, Beaudoin JC, Franco D, Balabaud C, Laurent-Puig P, Zucman-Rossi J: Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat Genet 32:312–315, 2002[Medline]
5. Reznik Y, Dao T, Coutant R, Chiche L, Jeannot E, Clauin S, Rousselot P, Fabre M, Oberti F, Fatome A, Zucman-Rossi J, Bellanne-Chantelot C: Hepatocyte nuclear factor-1 alpha gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families. J Clin Endocrinol Metab 89:1476–1480, 2004[Abstract/Free Full Text]
6. Menzel R, Kaisaki PJ, Rjasanowski I, Heinke P, Kerner W, Menzel S: A low renal threshold for glucose in diabetic patients with a mutation in the hepatocyte nuclear factor-1alpha (HNF-1alpha) gene. Diabet Med 15:816–820, 1998[Medline]
7. Fajans SS, Bell GI: Phenotypic heterogeneity between different mutations of MODY subtypes and within MODY pedigrees. Diabetologia 49:1106–1108, 2006[Medline]
8. Miedzybrodzka Z, Hattersley AT, Ellard S, Pearson D, de Silva D, Harvey R, Haites N: Non-penetrance in a MODY 3 family with a mutation in the hepatic nuclear factor 1alpha gene: implications for predictive testing. Eur J Hum Genet 7:729–732, 1999[Medline]
9. Hattersley AT: Maturity-onset diabetes of the young: clinical heterogeneity explained by genetic heterogeneity. Diabet Med 15:15–24, 1998[Medline]
10. Klupa T, Warram JH, Antonellis A, Pezzolesi M, Nam M, Malecki MT, Doria A, Rich SS, Krolewski AS: Determinants of the development of diabetes (maturity-onset diabetes of the young-3) in carriers of HNF-1alpha mutations: evidence for parent-of-origin effect. Diabetes Care 25:2292–2301, 2002[Abstract/Free Full Text]
11. Stride A, Shepherd M, Frayling TM, Bulman MP, Ellard S, Hattersley AT: Intrauterine hyperglycemia is associated with an earlier diagnosis of diabetes in HNF-1alpha gene mutation carriers. Diabetes Care 25:2287–2291, 2002[Abstract/Free Full Text]
12. Kim SH, Ma X, Klupa T, Powers C, Pezzolesi M, Warram JH, Rich SS, Krolewski AS, Doria A: Genetic modifiers of the age at diagnosis of diabetes (MODY3) in carriers of hepatocyte nuclear factor-1alpha mutations map to chromosomes 5p15, 9q22, and 14q24. Diabetes 52:2182–2186, 2003[Abstract/Free Full Text]
13. Jeannot E, Poussin K, Chiche L, Bacq Y, Sturm N, Scoazec JY, Buffet C, Van Nhieu JT, Bellanne-Chantelot C, de Toma C, Laurent-Puig P, Bioulac-Sage P, Zucman-Rossi J: Association of CYP1B1 germ line mutations with hepatocyte nuclear factor 1alpha-mutated hepatocellular adenoma. Cancer Res 67:2611–2616, 2007[Abstract/Free Full Text]
14. Ellard S, Colclough K: Mutations in the genes encoding the transcription factors hepatocyte nuclear factor 1 alpha (HNF1A) and 4 alpha (HNF4A) in maturity-onset diabetes of the young. Hum Mutat 27:854–869, 2006[Medline]
15. Bach I, Mattei MG, Cereghini S, Yaniv M: Two members of an HNF1 homeoprotein family are expressed in human liver. Nucleic Acid Res 19:3553–3559, 1991[Abstract/Free Full Text]
16. Harries LW, Ellard S, Stride A, Morgan NG, Hattersley AT: Isomers of the TCF1 gene encoding hepatocyte nuclear factor-1 alpha show differential expression in the pancreas and define the relationship between mutation position and clinical phenotype in monogenic diabetes. Hum Mol Genet 15:2216–2224, 2006[Abstract/Free Full Text]
17. Vaxillaire M, Abderrahmani A, Boutin P, Bailleul B, Froguel P, Yaniv M, Pontoglio M: Anatomy of a homeoprotein revealed by the analysis of human MODY3 mutations. J Biol Chem 274:35639–35646, 1999[Abstract/Free Full Text]
18. Harries LW, Hattersley AT, Ellard S: Messenger RNA transcripts of the hepatocyte nuclear factor-1alpha gene containing premature termination codons are subject to nonsense-mediated decay. Diabetes 53:500–504, 2004[Abstract/Free Full Text]
19. Chi YI, Frantz JD, Oh BC, Hansen L, Dhe-Paganon S, Shoelson SE: Diabetes mutations delineate an atypical POU domain in HNF-1alpha. Mol Cell 10:1129–1137, 2002[Medline]

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This Article Abstract Full Text (PDF) Online-Only Appendix All Versions of this Article: db07-0859v1 57/2/503    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bellanné-Chantelot, C. Articles by Timsit, J. Search for Related Content PubMed PubMed Citation Articles by Bellanné-Chantelot, C. Articles by Timsit, J. Social Bookmarking                What's this?